Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations

Authors

  • Niccolo Gori Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy; Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
  • Alvise Sernicola Dermatology Unit, Department of Medicine (DIMED), University of Padua, Padova, Italy
  • Elena Ippoliti Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy; Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
  • Rosa Coppola Dermatologia, Fondazione Policlinico, Universitario Campus Bio-Medico, Roma, Italy
  • Martina Maurelli Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
  • Michela Ortoncelli Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy
  • Claudia Paganini Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy; Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome, Italy
  • Ersilia Tolino Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Italy
  • Maria Mariano San Gallicano Dermatological Institute, IRCCS, Rome, Italy
  • Ester Del Duca Dermatology Clinic, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy
  • Gaia Moretta Department of Dermatology, Istituto Dermopatico dell’Immacolata -IRCCS, Dermatological Research Hospital, Rome, Italy
  • Vincenzo Panasiti Dermatologia, Fondazione Policlinico, Universitario Campus Bio-Medico, Roma, Italy
  • Giampiero Girolomoni Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
  • Simone Ribero Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy
  • Luisa Boeti Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy; Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
  • Luca Bianchi Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy; Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome, Italy
  • Maria Concetta Fargnoli San Gallicano Dermatological Institute, IRCCS, Rome, Italy
  • Giovanni Pellacani Dermatology Clinic, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy
  • Sabatino Pallotta Department of Dermatology, Istituto Dermopatico dell’Immacolata -IRCCS, Dermatological Research Hospital, Rome, Italy
  • Ketty Peris Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy; Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
  • Marco Galluzzo Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy; Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome, Italy

DOI:

https://doi.org/10.2340/actadv.v105.43523

Keywords:

atopic dermatitis, Dupilumab, special populations

Abstract

Dupilumab, the first biologic treatment approved for moderate to severe atopic dermatitis, has completely revolutionized the management of such disease allowing long-term control of its clinical signs and symptoms. Nevertheless, data regarding the safety and effectiveness profile of dupilumab in patients belonging to special populations are scarce. This observational, multicentric study analysed the effectiveness and safety profile of dupilumab over 3 years in the treatment of 70 patients with moderate to severe atopic dermatitis and associated comorbidities such as cancers, renal and liver failure, viral chronic infections, and degenerative and autoimmune neurological disorders. Patients achieved a significant improvement in both physician-assessed and patient-reported outcomes after 16 weeks of treatment, with a continuous therapeutic response maintained throughout the 156-week period. The safety profile was comparable to clinical trials and real-world data involving patients without significant comorbidities. In conclusion, the findings support the safety of dupilumab in managing severe atopic dermatitis in fragile patients.

Downloads

Download data is not yet available.

References

Gori N, Chiricozzi A, Marsili F, Ferrucci SM, Amerio P, Battarra V, et al. National information campaign revealed disease characteristic and burden in adult patients suffering from atopic dermatitis. J Clin Med 2022; 11: 5204. DOI: https://doi.org/10.3390/jcm11175204

Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers 2018; 4: 1. DOI: https://doi.org/10.1038/s41572-018-0001-z

Talamonti M, Galluzzo M, Silvaggio D, Lombardo P, Tartaglia C, Bianchi L. Quality of life and psychological impact in patients with atopic dermatitis. J Clin Med 2021; 10: 1298. DOI: https://doi.org/10.3390/jcm10061298

Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. SOLO 1 and SOLO 2 investigators: two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335–2348. DOI: https://doi.org/10.1056/NEJMoa1610020

Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo- controlled, phase 3 trial. Lancet 2017; 389: 2287–2303. DOI: https://doi.org/10.1016/S0140-6736(17)31191-1

Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol 2020; 82: 377–388. DOI: https://doi.org/10.1016/j.jaad.2019.07.074

Blauvelt A, Wollenberg A, Eichenfield LF, Zhang H, Sierka D, Khokhar FA, et al. No increased risk of overall infection in adults with moderate-to-severe atopic dermatitis treated for up to 4 years with dupilumab. Adv Ther 2023; 40: 367–380. DOI: https://doi.org/10.1007/s12325-022-02322-y

Fargnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A, et al. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat 2022; 33: 1146–1149. DOI: https://doi.org/10.1080/09546634.2020.1773379

Gori N, Sernicola A, Tolino E, Mariano M, Galluzzo M, Moretta G, et al. Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study. J Dermatolog Treat 2023; 34: 2230685. DOI: https://doi.org/10.1080/09546634.2023.2230685

Adam DN, Gooderham MJ, Beecker JR, Hong CH, Jack CS, Jain V, et al. Expert consensus on the systemic treatment of atopic dermatitis in special populations. J Eur Acad Dermatol Venereol 2023; 37: 1135–1148.

Patruno C, Potestio L, Scalvenzi M, Battista T, Raia F, Picone V, et al. Dupilumab for the treatment of adult atopic dermatitis in special populations. J Dermatolog Treat 2022; 33: 3028–3033. DOI: https://doi.org/10.1080/09546634.2022.2102121

Edmonds N, Zhao P, Flowers RH. The use of dupilumab in patients with HIV. Int J STD AIDS 2022; 33: 1165–1173. DOI: https://doi.org/10.1177/09564624221129406

Alawadhi A, Karibayeva D, Gottlieb AB. Dupilumab in HIV-positive patients: a case series report of 4 patients. JAAD Case Rep 2020; 6: 1356–1359. DOI: https://doi.org/10.1016/j.jdcr.2020.09.023

Avallone G, Trunfio M, Giura MT, Siliquini N, Viola R, Orofino G, et al. Dupilumab in HIV-positive patients with atopic dermatitis: a long-term follow-up patient and a literature review. Dermatol Online J 2021; 27. DOI: https://doi.org/10.5070/D327854709

Adam DN, Gooderham MJ, Beecker JR, Hong CH, Jack CS, Jain V, et al. Expert consensus on the systemic treatment of atopic dermatitis in special populations. J Eur Acad Dermatol Venereol 2023; 37: 1135–1148. DOI: https://doi.org/10.1111/jdv.18922

Ly K, Smith MP, Thibodeaux Q, Beck K, Bhutani T, Liao W. Dupilumab in patients with chronic hepatitis B on concomitant entecavir. JAAD Case Rep 2019 2; 5: 624–626. DOI: https://doi.org/10.1016/j.jdcr.2019.05.007

Mota F. Atopic dermatitis patient with hepatitis C treated with dupilumab: a case report. Actas Dermosifiliogr 2024; 115: 420–421. DOI: https://doi.org/10.1016/j.ad.2022.07.038

Braddock M, Hanania NA, Sharafkhaneh A, Colice G, Carlsson M. Potential risks related to modulating interleukin-13 and interleukin-4 signalling: a systematic review. Drug Saf 2018; 41: 489–509. DOI: https://doi.org/10.1007/s40264-017-0636-9

Metko D, Alkofide M, Abu-Hilal M. A real-world study of dupilumab in patients with atopic dermatitis including patients with malignancy and other medical comorbidities. JAAD Int 2024; 15: 5–11. DOI: https://doi.org/10.1016/j.jdin.2024.01.002

Tanczosova M, Hugo J, Gkalpakiotis S. Treatment of severe atopic dermatitis with dupilumab in patients with advanced cancer. J Clin Med 2023; 12: 1191. DOI: https://doi.org/10.3390/jcm12031191

Siliquini N, Giura MT, Viola R, Ribero S, Panzone M, Dapavo P, et al. Atopic dermatitis, dupilumab and cancers: a case series. J Eur Acad Dermatol Venereol 2021; 35: e651–652. DOI: https://doi.org/10.1111/jdv.17264

Talmon A, Elias S, Rubin L, Ribak Y, Ben Dori E, Shamriz O, et al. Dupilumab for cancer-associated refractory pruritus. J Allergy Clin Immunol Glob 2023; 2: 100128. DOI: https://doi.org/10.1016/j.jacig.2023.100128

Thyssen JP, Halling AS, Schmid-Grendelmeier P, Guttman-Yassky E, Silverberg JI. Comorbidities of atopic dermatitis: what does the evidence say? J Allergy Clin Immunol 2023; 151: 1155–1162. DOI: https://doi.org/10.1016/j.jaci.2022.12.002

Jalles C, Lepelley M, Mouret S, Charles J, Leccia MT, Trabelsi S. Skin cancers under Janus kinase inhibitors: a World Health Organization drug safety database analysis. Therapie 2022; 77: 649–656. DOI: https://doi.org/10.1016/j.therap.2022.04.005

Hasan I, Parsons L, Duran S, Zinn Z. Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study. J Am Acad Dermatol 2024; 91: 255–258. DOI: https://doi.org/10.1016/j.jaad.2024.03.039

Stuver R, Dusza S, Epstein-Peterson ZD, Ghione P, Horwitz SM, Johnson W, et al. Cutaneous T-cell lymphoma and dupilumab use: a retrospective matched cohort study of clinical characteristics and treatment outcomes. J Eur Acad Dermatol Venereol 2025; 39: e114–e117. DOI: https://doi.org/10.1111/jdv.20141

Mazzetto R, Miceli P, Tartaglia J, Ciolfi C, Sernicola A, Alaibac M. Role of IL-4 and IL-13 in cutaneous T cell lymphoma. Life (Basel) 2024; 14: 245. DOI: https://doi.org/10.3390/life14020245

Patruno C, Fabbrocini G, Longo G, Argenziano G, Ferrucci SM, Stingeni L, et al. Effectiveness and safety of long-term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter real-life observational study. Am J Clin Dermatol 2021; 22: 581–586. DOI: https://doi.org/10.1007/s40257-021-00597-5

Foti C, Romita P, Ambrogio F, Manno C, Filotico R, Cassano N, et al. Treatment of severe atopic dermatitis with dupilumab in three patients with renal diseases. Life (Basel). 2022; 12: 2002. DOI: https://doi.org/10.3390/life12122002

Laageide L, Verhave B, Samkoff L, Looney R, Beck L. Relapsing-remitting multiple sclerosis arising in a patient with atopic dermatitis on dupilumab. JAAD Case Rep 2021; 15: 33–35. DOI: https://doi.org/10.1016/j.jdcr.2021.07.003

Gelato F, Mastorino L, Cavalla P, Quaglino P, Cavaliere G, Vercellino M, et al. Onset of multiple sclerosis in a patient on dupilumab therapy for atopic dermatitis: a case report. Dermatol Ther 2022; 35: e15740. DOI: https://doi.org/10.1111/dth.15740

Esposito M, De Berardinis A, Totaro R, Fargnoli MC. Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis. JAAD Case Rep 2023; 31: 1–5. DOI: https://doi.org/10.1016/j.jdcr.2022.10.031

Downloads

Published

2025-10-02

How to Cite

Gori, N., Sernicola, A., Elena Ippoliti, Coppola, R., Maurelli, M., Ortoncelli, M., … Galluzzo, M. (2025). Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations. Acta Dermato-Venereologica, 105, adv43523. https://doi.org/10.2340/actadv.v105.43523

Issue

Vol. 105 (2025)

Section

Articles

Categories

License

Copyright (c) 2025 Niccolo Gori, Alvise Sernicola, Elena Ippoliti, Rosa Coppola, Martina Maurelli, Michela Ortoncelli, Claudia Paganini, Ersilia Tolino, Maria Mariano, Ester Del Duca, Gaia Moretta, Vincenzo Panasiti, Giampiero Girolomoni, Simone Ribero, Luisa Boeti, Luca Bianchi, Maria Concetta Fargnoli, Giovanni Pellacani, Sabatino Pallotta, Ketty Peris, Marco Galluzzo

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.

Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.

Crossref
Scopus
Google Scholar
Europe PMC